H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Parker PM, Stein AS, et al. High-dose chemotherapy with or<br />
without total body irradiat<strong>io</strong>n fol<strong>lo</strong>wed by auto<strong>lo</strong>gous bone<br />
marrow and/or peripheral b<strong>lo</strong>od stem cell transplantat<strong>io</strong>n for<br />
patients with relapsed and refractory Hodgkin’s disease:<br />
results in 85 patients with analysis of prognostic factors.<br />
B<strong>lo</strong>od. 1995 85:1381-90.<br />
6. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A,<br />
Bishop MR, et al. High-dose chemotherapy fol<strong>lo</strong>wed by auto<strong>lo</strong>gous<br />
hematopoietic rescue for Hodgkin’s disease patients fol<strong>lo</strong>wing<br />
first relapse after chemotherapy. Ann Oncol. 1996 7:151-6.<br />
7. Caballero MD, Rub<strong>io</strong> V, Rifón J, Heras I, García-Sanz R,<br />
Vázquez L, et al. BEAM chemotherapy fol<strong>lo</strong>wed by auto<strong>lo</strong>gous<br />
stem cell support in lymphoma patients: analysis of efficacy,<br />
toxicity and prognostic factors. Bone Marrow<br />
Transplant. 1997;20:451-8.<br />
8. Sureda A, Arranz R, Ir<strong>io</strong>ndo A, Carreras E, Lahuerta JJ, García-<br />
Conde J, et al. Auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n for<br />
Hodgkin’s disease: Results and prognostic factors in 494<br />
patients from the GEL/TAMO Spanish Cooperative Group. J<br />
Clin Oncol. 2001;19:1395-404.<br />
9. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN,<br />
Klingemann HG, et al. Intensive therapy with cyc<strong>lo</strong>phosphamide,<br />
carmustine, etoposide ± cisplatin, and auto<strong>lo</strong>gous<br />
bone marrow transplantat<strong>io</strong>n for Hodgkin’s disease in first<br />
relapse after combinat<strong>io</strong>n chemotherapy. B<strong>lo</strong>od. 1994;83:1193-9.<br />
10. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B,<br />
McMillan A, et al. Dose intensificat<strong>io</strong>n with auto<strong>lo</strong>gous bonemarrow<br />
transplantat<strong>io</strong>n in relapsed and re¬sistant Hodgkin’s disease:<br />
results of a BNLI randomized trial. Lancet. 1993;341:1051-4.<br />
11. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM,<br />
Haenel M, et al. Aggressive convent<strong>io</strong>nal chemotherapy<br />
com¬pared with high-dose chemotherapy requiring auto<strong>lo</strong>gous<br />
haemopoietic stem cell trans¬plantat<strong>io</strong>n for relapsed<br />
chemosensitive Hodgkin’s disease: a randomised trial. Lancet.<br />
2002;359:2065-71.<br />
12. Schmitz N, Haverkamp H, Josting A, Sextro M, Sieber M,<br />
Carella AM, et al. Long-term results of HD-R1: Convent<strong>io</strong>nal<br />
chemotherapy compared with high-dose chemotherapy with<br />
auto<strong>lo</strong>gous haemopoietic stem cell transplantat<strong>io</strong>n in relapsed<br />
Hodgkin’s disease. Eur J Hematol. 2004;73(suppl. 65):R16.<br />
13. Josting A, Sieniawski M, G<strong>lo</strong>ssmann JP, Staak O, Nogova L,<br />
Peters N, et al. High-dose sequential chemotherapy fol<strong>lo</strong>wed<br />
by auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n in relapsed and refractory<br />
aggressive non-Hodgkin’s lymphoma: results of a multicenter<br />
phase II study. Ann Oncol. 2005;16:1359-65.<br />
14. Josting A, Müller H, Borchmann P, Baars JW, Metzner B,<br />
Döhner H, et al. Dose intensity of chemotherapy in patients<br />
with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28:<br />
5074-80.<br />
15. Sweetenham JW, Carella AM, Taghipour G, Cunningham D,<br />
Marcus R, Della Volpe A, et al. High dose therapy and auto<strong>lo</strong>gous<br />
stem cell transplantat<strong>io</strong>n for adult patients with<br />
Hodgkin’s disease who fail to enter remiss<strong>io</strong>n after induct<strong>io</strong>n<br />
chemotherapy: Results in 175 patients reported to the EBMT.<br />
J Clin Oncol. 1999;17:3101-3109.<br />
16. Lazarus HM, Rowlings PA, Zhang M-J, Vose JM, Armitage JO,<br />
Bierman PJ, et al. Autotransplants for Hodgkin’s disease in<br />
patients never achieving remiss<strong>io</strong>n: A report from the<br />
Auto<strong>lo</strong>gous B<strong>lo</strong>od and Marrow Transplant Registry. J Clin<br />
Oncol. 1999;17:534-45.<br />
17. Constans M, Sureda A, Terol M J, Arranz R, Caballero MD,<br />
Ir<strong>io</strong>ndo A, Jarque I, et al. Auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n<br />
for primary refractory Hodgkin’s disease: results and clinical<br />
variables affecting outcome. Ann Oncol. 2003;14:745-51.<br />
18. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A,<br />
Reman O, et al. Intensive salvage therapy with high-dose<br />
chemotherapy for patients with advanced Hodgkin’s disease<br />
in relapse or failure after initial chemotherapy: Results of the<br />
Groupe d’Études des Lymphomes de l’adulte H89 trial. J Clin<br />
Oncol. 2002;20:467-75.<br />
19. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M,<br />
Zelenetz AD, Yaha<strong>lo</strong>m J. Effectiveness of high dose chemorad<strong>io</strong>therapy<br />
and auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n for<br />
patients with b<strong>io</strong>psy-proven primary refractory Hodgkin’s<br />
disease. Br J Haematol. 2004;124:645-52.<br />
20. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A.<br />
Prognostic factors and treatment outcome in primary progressive<br />
Hodgkin lymphoma: a report from the German Hodgkin<br />
Lymphoma Study Group. B<strong>lo</strong>od. 2000;96:1280-6<br />
21. Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L,<br />
et al. Factors associated with survival in patients with progressive<br />
disease fol<strong>lo</strong>wing auto<strong>lo</strong>gous transplant for lymphoma.<br />
Bone Marrow Transplant. 2003;31:565-9.<br />
22. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J,<br />
London, United Kingdom, June 9-12, 2011<br />
Yaha<strong>lo</strong>m J, et al. Progressive disease fol<strong>lo</strong>wing auto<strong>lo</strong>gous transplantat<strong>io</strong>n<br />
in patients with chemosensitive relapsed or primary<br />
refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma.<br />
Bone Marrow Transplant. 2003;32:673-9.<br />
23. Constans M, Sureda A, Arranz R, Caballero MD, Carreras E,<br />
Conde E, et al. Relapse after auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n<br />
for Hodgkin’s lymphoma: prognostic factors affecting<br />
<strong>lo</strong>ng-term outcome. Eur J Haematol. 2004;73:53.<br />
24. Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D,<br />
Pulsoni A, et al. Rewlapse of Hodgkin’s Lymphoma after<br />
auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n (ASCT): Identificat<strong>io</strong>n of<br />
prognostic factors predicting outcome. B<strong>lo</strong>od. (submitted).<br />
25. Brice P, Bouabdallah R, Moreau P, Divine M, André M,<br />
Aoudjane M, et al. Prognostic factors for survival after highdose<br />
therapy and auto<strong>lo</strong>gous stem cell transplantat<strong>io</strong>n for<br />
patients with relapsing Hodgkin’s Disease: analysis of 280<br />
patients from the French Registry, Societe Francaise de Greffe<br />
de Moelle. Bone Marrow Transplant. 1997;20:21-26.<br />
26. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et<br />
al. New prognostic score based on treatment outcome of<br />
patients with relapsed Hodgkin’s Lymphoma registered in the<br />
Database of the German Hodgkin’s Lymphoma Study Group.<br />
J Clin Oncol. 2002;20:221-30.<br />
27. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick<br />
EE, Filippa DA, et al. A 2-step comprehensive high-dose<br />
chemorad<strong>io</strong>therapy second-line program for relapsed and<br />
refractory Hodgkin’s disease: analysis by intent-to-treat and<br />
deve<strong>lo</strong>pment of a prognostic model. B<strong>lo</strong>od. 2001;97:616-23.<br />
28. Tarella C, Cuttica A, Vito<strong>lo</strong> U, Liberati M, Di Nicola M,<br />
Cortelazzo S, et al. High-dose sequential chemotrherapy and<br />
peripheral b<strong>lo</strong>od progenitor cell autografting in patients with<br />
refractory and/or recurrent Hodgkin’s lymphoma: a multicenter<br />
study of the Intergruppo Italiani Lymphomi showing pro<strong>lo</strong>nged<br />
disease free survival in patients treated at first recurrence.<br />
Cancer 2003;97:2748-59.<br />
29. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff G, Pruim J,<br />
Vaalburg W, et al. Early FDG-PET assessment in combinat<strong>io</strong>n<br />
with clinical risk scores determines prognosis in recurrent<br />
lymphomas. B<strong>lo</strong>od. 2007;109:486-91.<br />
30. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, et al.<br />
Pretransplant positive positron emiss<strong>io</strong>n tomography/gallium<br />
scans predict poor outcome in patients with recurrent/refractory<br />
Hodgkin’s lymphoma. Cancer. 2007;109:2481-9.<br />
31. Appelbaum FR, Sullivan KM, Thomas ED, Buckner CD, Clift<br />
RA, Deeg HJ et al. Al<strong>lo</strong>geneic marrow transplantat<strong>io</strong>n in the<br />
treatment of MOPP-resistant Hodgkin’s disease. J Clin Oncol.<br />
1985;3:1490-94.<br />
32. Phillips GL, Reece DE, Barnett MJ, Connors JM, Fay JW,<br />
Herzig GP, et al. Al<strong>lo</strong>geneic marrow transplantat<strong>io</strong>n for<br />
re¬fractory Hodgkin’s disease. J Clin Oncol. 1989;7:1039-45.<br />
33. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale<br />
RP, Champlin RE, et al. Bone marrow transplants from HLAidentical<br />
siblings in advanced Hodgkin’s disease. J Clin Oncol.<br />
1996;14:572-8.<br />
34. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH.<br />
Al<strong>lo</strong>geneic bone marrow transplant is not better than auto<strong>lo</strong>gous<br />
transplant for patients with relapsed Hodgkin’s disease. J<br />
Clin Oncol. 1996;14:1291-6.<br />
35. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD,<br />
Buckner CD, et al. Al<strong>lo</strong>geneic, syngeneic, and auto<strong>lo</strong>¬gous<br />
marrow transplantat<strong>io</strong>n for Hodgkin’s disease: The 21-year<br />
Seattle Experience. J Clin Oncol. 1993;11:2342-50.<br />
36. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of<br />
a graft-versus-lymphoma effect associated with al<strong>lo</strong>geneic<br />
bone marrow transplantat<strong>io</strong>n. B<strong>lo</strong>od. 1991;77:649-53.<br />
37. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky<br />
RA, Vogelsang GB, et al. Long-term results of b<strong>lo</strong>od and marrow<br />
transplantat<strong>io</strong>n for Hodgkin’s disease. J Clin Oncol.<br />
2001;19:4314-21.<br />
38. Robinson S, Sureda A, Canals C, Russell N, Caballero D,<br />
Bacigalupo A, et al. Reduced intensity al<strong>lo</strong>geneic stem cell transplantat<strong>io</strong>n<br />
for Hodgkin’s lymphoma: Identificat<strong>io</strong>n of prognostic<br />
factors predicting outcome. Haematol. 2008;94:230-8.<br />
39. Anderlini P, Saliba R, Acho<strong>lo</strong>nu S, Okoroji GJ, Donato M,<br />
Giralt S, et al. Reduced-intensity al<strong>lo</strong>geneic stem cell transplantat<strong>io</strong>n<br />
in relapsed and refractory Hodgkin’s disease: <strong>lo</strong>w<br />
transplant-related mortality and impact of intensity of condit<strong>io</strong>ning<br />
regimen. Bone Marrow Transplant. 2005;35:943-51.<br />
40. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera<br />
JM, Canales M, et al. Non-mye<strong>lo</strong>ablative stem cell transplantat<strong>io</strong>n<br />
is an effective therapy for refractory or relapsed<br />
Hodgkin’s lymphoma: Results of a Spanish prospective cooperative<br />
protocol. B<strong>io</strong>l B<strong>lo</strong>od Marrow Transplant. 2006; 12: 172-<br />
183.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 171 |
Change language